In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
Publication
, Journal Article
Kelsey, M; Newby, LK
Published in: Ann Intern Med
April 2024
Ray KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12:19-28. 38061370.
Duke Scholars
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
April 2024
Volume
177
Issue
4
Start / End Page
JC39
Location
United States
Related Subject Headings
- Randomized Controlled Trials as Topic
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- General & Internal Medicine
- Fatty Acids
- Dicarboxylic Acids
- Diabetes Mellitus
- Adult
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelsey, M., & Newby, L. K. (2024). In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y. Ann Intern Med, 177(4), JC39. https://doi.org/10.7326/J24-0016
Kelsey, Michelle, and L Kristin Newby. “In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.” Ann Intern Med 177, no. 4 (April 2024): JC39. https://doi.org/10.7326/J24-0016.
Kelsey M, Newby LK. In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y. Ann Intern Med. 2024 Apr;177(4):JC39.
Kelsey, Michelle, and L. Kristin Newby. “In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.” Ann Intern Med, vol. 177, no. 4, Apr. 2024, p. JC39. Pubmed, doi:10.7326/J24-0016.
Kelsey M, Newby LK. In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y. Ann Intern Med. 2024 Apr;177(4):JC39.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
April 2024
Volume
177
Issue
4
Start / End Page
JC39
Location
United States
Related Subject Headings
- Randomized Controlled Trials as Topic
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- General & Internal Medicine
- Fatty Acids
- Dicarboxylic Acids
- Diabetes Mellitus
- Adult
- 3202 Clinical sciences
- 11 Medical and Health Sciences